Test Price
2,800 AED✅ Home Collection Available
CACNA1D Gene Sequencing Test – Sinoatrial Node Dysfunction & Deafness (SANDD) in UAE | 2800 AED
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited next-generation sequencing (NGS) processing.
- Premium Logistics: VIP Mobile Phlebotomy & temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Post-test telephonic consultation with a DHA-licensed consultant medical geneticist and genetic counsellor.
- Direct Billing: Insurance verification and direct billing support via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
This next-generation sequencing (NGS) test analyses the entire CACNA1D gene for pathogenic variants linked to sinoatrial node dysfunction and deafness (SANDD). Designed for patients with unexplained bradycardia, sick sinus syndrome, or progressive sensorineural hearing loss, it pinpoints the underlying genetic cause to guide personalised cardiac and audiological management.
| Feature | Our Test (NGS) | Closest Alternative (Sanger) |
|---|---|---|
| Methodology | High‑throughput NGS, full gene coding plus deep intronic regions | Exon‑by‑exon Sanger sequencing |
| Turnaround Time | 3 to 4 Weeks | 6 to 8 Weeks |
| Sensitivity | 99.9% for single nucleotide variants and small insertions/deletions | ~95% (misses deep intronic mutations) |
| Price (AED) | 2,800 | 3,500 |
Physician Insight & Safety Protocols
“As a consultant medical genetics specialist, I emphasise that CACNA1D gene sequencing provides critical molecular evidence for patients presenting with sinoatrial node dysfunction and deafness. Identifying a pathogenic variant enables cascade screening for at-risk family members and facilitates tailored surveillance strategies. However, genetic findings must always be interpreted within the full clinical picture, including cardiac electrophysiology and audiological assessment. A positive result does not automatically predict disease severity, and management decisions should be made collaboratively with your treating cardiologist and audiologist.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Important Medication Advisory
Medication Advisory
Do not discontinue prescribed cardiac medications such as antiarrhythmics or beta‑blockers, nor any hearing loss therapies, without consulting your treating physician. Abrupt cessation may worsen underlying symptoms.
Exclusion Criteria & Safety Red Flags
Before Sample Collection
- Severe anaemia (haemoglobin below 7 g/dL) or active bleeding disorder
- Uncontrolled coagulopathy or INR greater than 3.0
- Recent major surgery within 72 hours without haematologist clearance
Emergency Red Flags – Seek Urgent Care
- Syncope or near‑syncope accompanied by bradycardia
- Chest pain, dyspnoea, or severe dizziness
- Sudden hearing loss accompanied by vertigo
Patient FAQ & Clinical Guidance
1. What is the CACNA1D gene test and why is it prescribed?
This genetic test uses next‑generation sequencing to identify mutations in the CACNA1D gene that cause sinoatrial node dysfunction and progressive deafness (SANDD syndrome). It is prescribed when a patient presents with unexplained slow heart rate, sick sinus syndrome, or sensorineural hearing loss with a suspected hereditary basis, enabling precise clinical management and family counselling.
2. How is the sample collected for this test?
A certified phlebotomist collects a peripheral whole blood sample (standard venipuncture) during a scheduled home visit or at our Dubai Healthcare City facility. For select cases, a finger‑prick dried blood spot on an FTA card may be used. Our VIP Mobile Phlebotomy service operates daily from 8 AM to 11 PM with temperature‑controlled cold‑chain transport.
3. When will I receive my results, and how are they delivered?
Results are issued within 3 to 4 weeks of sample receipt. You will receive a detailed genetic report along with a telephonic post‑test consultation with a DHA‑licensed consultant medical geneticist or genetic counsellor who will explain the findings, discuss clinical implications, and coordinate referrals to cardiology or audiology specialists as needed.
4. Does insurance cover this test, and can I get direct billing?
We work with most major UAE insurance providers. Direct billing verification can be arranged through our WhatsApp support line at +971 54 548 8731. Please have your insurance policy details and referral letter ready for a swift pre‑authorisation process.
5. Can this test be performed on children or infants?
Yes. Genetic testing for SANDD can be performed at any age when clinically indicated. For minors, written informed consent from a parent or legal guardian is mandatory, and pre‑test genetic counselling is recommended to discuss the implications of result disclosure.
UAE Regulatory & Data Privacy Adherence
- Licensed by the Dubai Health Authority (DHA) – Facility License Number: 1143
- Compliant with Federal Decree‑Law No. 45 of 2021 on the Protection of Personal Data (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields
- Clinical safety and informed consent protocols adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability
- ISO 9001:2015 Certified Quality Management System – all genetic testing includes mandatory pre‑test counselling to document family pedigree and confirm clinical history of sinoatrial node dysfunction and deafness
- Secure medical courier solid tissue specimen retrieval available for archival samples; all genetic data stored encrypted and access‑controlled
Contact & Support: +971 54 548 8731 (Phone and WhatsApp)
Clinical & Logistical Metadata
| Test Name | CACNA1D Gene Sequencing – Sinoatrial Node Dysfunction & Deafness (SANDD) |
| Price (AED) | 2,800 |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA) or dried blood spot (FTA card) |
| Methodology Used | Next‑Generation Sequencing (NGS) – full gene coding regions plus deep intronic regions |
| ICD-10-CM Code | I49.5 (Sick sinus syndrome), H90.3 (Sensorineural hearing loss, bilateral) |
| LOINC Code | 82939-0 (DNA sequencing panel) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians